Serotonin receptors: Clinical implications

https://doi.org/10.1016/S0149-7634(05)80158-7Get rights and content

Over the past decade, a variety of serotonin (5-hydroxytryptamine, 5-HT) receptor/binding sites have been identified. These include 5-HT1, 5-HT2, and 5-HT3 sites. The 5-HT1 sites have been further divided into 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D and 5-HT1E sites. It would be of interest to identify those pharmacological effects that are specifically mediated by a particular population of 5-HT sites and, indeed, attempts have been made to do this almost since the initial discovery of multiple populations of sites. Unfortunately, much of the early work made use of serotonergic agents that are now known to be somewhat less selective than originally suspected. Nevertheless, there is ample information in the literature suggesting that site-selective serotonergic agents may ultimately lead (and, in some cases, has already led) to the development of therapeutically-useful agents. The present review examines the pharmacological effects that are thought to be related to the individual types of 5-HT sites and provides some clinical implications for agents that act at these sites.

References (183)

  • GardnerC.R.

    Recent developments in 5HT-related pharmacology of animal models of anxiety

    Pharmacol. Biochem. Behav.

    (1986)
  • GiralP. et al.

    Pharmacological evidence for the involvement of 1-(2-pyridinyl)piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systems

    Eur. J. Pharmacol.

    (1987)
  • GlaserT. et al.

    Buspirone: action on serotonin receptors in calf hippocampus

    Eur. J. Pharmacol.

    (1983)
  • GlennonR.A. et al.

    Mechanistic studies on DOM as a discriminative stimulus

    Pharmacol. Biochem. Behav.

    (1985)
  • HaganR.M. et al.

    Effects of the 5-HT3 antagonist GR 38032F on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain

    Eur. J. Pharmacol.

    (1987)
  • HartigP.R.

    Molecular biology of 5-HT receptors

    Trends Pharmacol. Sci.

    (1989)
  • HewsonG. et al.

    Ketanserin antagonizes the anorectic effect of dl-fenfluramine in the rat

    Eur. J. Pharmacol.

    (1988)
  • HutsonP.H. et al.

    Hypothermia induced by the putative 5-HT1A agonist LY165163 and 8-OH DPAT is not prevented by 5-HT depletion

    Eur. J. Pharmacol.

    (1987)
  • HutsonP.H. et al.

    Neurochemical and behavioural evidence for mediation of the hyperphagic action of 8-OH DPAT by cell body autoreceptors

    Eur. J. Pharmacol.

    (1986)
  • KennettG.A. et al.

    Single administration of 5-HT1A agonists decreases 5-HT1A presynaptic, but not postsynaptic receptor-mediated responses: Relationship to antidepressant-like action

    Eur. J. Pharmacol.

    (1987)
  • AhleniusS. et al.

    Evidence for a unique pharmacological profile of 8-OH DPAT by evaluation of its effects on male rat sexual behavior

  • AldousF.A.B. et al.

    Structure-activity relationships in psychotomimetic phenalkylamines

    J. Med. Chem.

    (1974)
  • Al-YassiriM.M. et al.

    Minireview: Trazodone—A new antidepressant

    Life Sci.

    (1981)
  • ArriagaF. et al.

    Ritanserin, an original sleep quality improving agent in generalized anxiety disorders

  • AwoutersF. et al.

    Pharmacological profile of ritanserin: A very specific central serotonin S2-antagonist

    Drug Dev. Res.

    (1988)
  • BevanP. et al.

    The behavioral pharmacology of 5-HT

    (1989)
  • BradfordL.D. et al.

    The pharmacology of fluprazine

  • BreckenridgeA.M. et al.

    The role of serotonin in cardiovascular disease

  • BrileyM.

    Imipramine binding: Its relationship with serotonin

  • BrittainR.T. et al.

    GR 38032F: A novel selective 5-HT3 antaonist

    Br. J. Pharmacol.

    (1987)
  • BroekkampC.L. et al.

    The relationship between various animal models of anxiety, fear-related psychiatric symptoms and response to serotonergic drugs

  • BurrisK.D. et al.

    Hallucinogens directly activate serotonin 5-HT1C receptors in choroid plexus

    Soc. Neurosci. Abstr.

    (1988)
  • CacciaS. et al.

    1-(2-Pyrimidinyl)piperazine as active metabolite of buspirone in man and rat

    Pharmacology

    (1986)
  • CarlssonM. et al.

    Comparison between male and female rats with respect to behavioral, biochemical, hypothermic and prolactin-releasing effects of 8-OH DPAT

  • CeulemansD. et al.

    The influence of ritanserin, a serotonin antagonist, in anxiety disorders: A double-blind placebo-controlled study vs. lorazepam

    Pharmacopsychiatry

    (1985)
  • CeulemansD. et al.

    Serotonin blockade or benzodiazepines: What kind of anxiolysis

  • ChaputY. et al.

    Effect of 1-PP on alpha-2 adrenoceptors: Electrophysiological studies in the rat central nervous system in vivo

    Soc. Neurosci. Abstr.

    (1988)
  • CharneyD.S. et al.

    Serotonin function in anxiety II. Effects of the serotonin agonist MCPP in panic order patients and in helathy volunteers

    Psychopharmacology (Berlin)

    (1987)
  • ClarkeW.P. et al.

    Estrogen enhances serotonin-1A electrophysiological responses in female rat hippocampal slices

    Soc. Neurosci. Abstr.

    (1988)
  • ColpaertF.C. et al.

    Behavioral and 5-HT antagonist effects of ritanserin: A pure and selective antagonist of LSD discrimination in rats

    Psychopharmacology (Berlin)

    (1985)
  • CooperS.J.

    Palatability-induced food consumption is stimulated by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH DPAT)

  • CoscinaD.V. et al.

    Effect of housing and pre-test handling on the hyperphagic and hypothermic effects of 8-OH DPAT

    Soc. Neurosci. Abstr.

    (1988)
  • CostallB. et al.

    The anxiolytic activity of GR38032F in the mouse and marmoset

    Br. J. Pharmacol.

    (1987)
  • CostalB. et al.

    Recent advances in the neuropharmacology of 5-HT3 agonists and antagonists

    Rev. Neurosci.

    (1988)
  • CritchleyM.A.E. et al.

    Anxiogenic-like effects of three 5-HT agonists

    Psychopharmacology (Berlin)

    (1986)
  • CritchleyM.A.E. et al.

    Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors

    Psychopharmacology (Berlin)

    (1987)
  • CritchleyM.A.E. et al.

    Prevention of 8-OH DAPT anxiogenic effect by ipsapirone and by 5-HT1 antagonist ß-adrenoceptor antagonists

    Br. J. Pharmacol.

    (1988)
  • CroissantD. et al.

    Estrous cycle changes in 5-HT1A binding sites and the 5-HT syndrome

    Soc. Neurosci. Abstr.

    (1988)
  • CrossA.J.

    Serotonin in neurodegenerative disorders

  • DavisM. et al.

    Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: Comparison with 8-OH DPAT and ipsapirone

    Psychopharmacology (Berlin)

    (1988)
  • Cited by (203)

    • The serotonin 2C receptor agonist WAY-163909 attenuates ketamine-induced hypothermia in mice

      2019, European Journal of Pharmacology
      Citation Excerpt :

      5-HT2C receptors are the most abundantly expressed serotonin receptor in the hypothalamus (Yadav et al., 2009). 5-HT2 receptors have been reported to increase vasoconstriction in the viscera and skin (Glennon, 1990). Previous studies have linked the 5-HT2A receptor to thermoregulation (Ootsuka and Blessing, 2006; Pawlyk et al., 2006; Sipe et al., 2004).

    • Design, synthesis and pharmacological evaluation of some novel derivatives of 1-{[3-(furan-2-yl)-5-phenyl-4,5-dihydro-1,2-oxazol-4-yl]methyl}-4-methyl piperazine

      2017, Arabian Journal of Chemistry
      Citation Excerpt :

      In addition, anxiety and depression are conceived to be different neuropsychiatric diseases, there is considerable overlap among the clinical symptoms of these disorders and differential diagnosis is often difficult (Tyrer, 1992). Anxiety often coexists with depression or may precede the development of depressive symptoms (Nutt and Glue, 1989) and anxiety and depression may be biochemically colligated since there are many similarities in the neurological substrates thought to play a role in these diseases, (Glennon and Dukat, 1995; Heninger, 1995; Sleight et al., 1991; Siever et al., 1991; Perregaard et al., 1993; Glennon, 1990; Zifa and Fillion, 1992) including a recent report describing a polymorphism in the serotonin transporter gene associated with both anxiety and depression-related personality traits (Lesch, 1998). In accession, anxiolytic agents may have utility in treating depression, (Charney et al., 1990) and there is developing clinical evidence that antidepressants may be effective in treating generalized anxiety disorder (Rickels et al., 1993).

    • The anxiogenic-like effects of dehydration in a semi-desert rodent Meriones shawi indicating the possible involvement of the serotoninergic system

      2012, Acta Histochemica
      Citation Excerpt :

      In addition, the implication of serotonin 2A receptors has been shown in some types of anxiety disorders, especially panic disorders (Ho-Kyoung et al., 2008), and a significant association between the severity of the panic symptoms and the serotonin 2A receptor gene has been reported (Ho-Kyoung et al., 2008). Nevertheless, there are many controversies about the exact role of 5-HT in anxiety (Glennon, 1990; Handley, 1995). Several authors have demonstrated that reduction in 5-HT neurotransmission decreases anxiety, whereas stimulation of the 5-HT system results in an anxiogenic effect (Dumuis et al., 1988; Charney et al., 1990; Lucki, 1992).

    • [<sup>18</sup>F]MPPF as a tool for the in vivo imaging of 5-HT<inf>1A</inf> receptors in animal and human brain

      2007, Neuropharmacology
      Citation Excerpt :

      In this context, some discrepancies between postmortem studies of human brain could potentially be resolved with [18F]MPPF PET imaging studies in vivo. As already mentioned, 5-HT1A receptors are implicated in a number of CNS diseases, including psychiatric disorders, such as depression, anxiety and schizophrenia (Kostowski et al., 1989; Glennon, 1990; Saudou and Hen, 1994; Peroutka, 1995; Saxena, 1995). As an [18F]MPPF PET database of healthy subjects has only been recently available, no clinical study has yet been published at this time with these types of patients.

    View all citing articles on Scopus
    View full text